Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hetrombopag in adults with primary immune thrombocytopenia
CTR20170792Phase 3Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of hetrombopag in immune thrombocytopenia (ITP), sponsored by Hengrui Therapeutics. Started Jul 2017; status: completed.
02
Drugs
hetrombopag
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on CTR20170792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170792.